Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update

World Journal of Gastroenterology

Volumn 22, Issue 24, 2016, Pages 5505-5511

  Scaldaferri, Franco ^a   Gerardi, Viviana ^a   Mangiola, Francesca ^a   Lopetuso, Loris Riccardo ^a   Pizzoferrato, Marco ^a   Petito, Valentina ^a   Papa, Alfredo ^a   Stojanovic, Jovana ^a   Poscia, Andrea ^a   Cammarota, Giovanni ^a   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Escherichia coli Nissle; Inflammatory bowel disease; Metanalysis; Probiotic; Randomized trial; Ulcerative colitis

Indexed keywords

CIPROFLOXACIN; HYDROCORTISONE; MESALAZINE; MUTAFLOR; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSENCE OF SIDE EFFECTS; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; COLITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; HUMAN; IMMUNOMODULATION; NONHUMAN; REMISSION; REVIEW; SINGLE DRUG DOSE; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; MAINTENANCE CHEMOTHERAPY; MICROBIOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; ESCHERICHIA COLI; HUMANS; MAINTENANCE CHEMOTHERAPY; MESALAMINE; PROBIOTICS;

EID: 84978969338     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i24.5505     Document Type: Review

References (41)

1. Sartor RB. Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407 [PMID: 16819502 DOI: 10.1038/ncpgasthep0528]
2. Scaldaferri F, Gerardi V, Lopetuso LR, Del Zompo F, Mangiola F, Boškoski I, Bruno G, Petito V, Laterza L, Cammarota G, Gaetani E, Sgambato A, Gasbarrini A. Gut microbial flora, prebiotics, and probiotics in IBD: Their current usage and utility. Biomed Res Int 2013; 2013: 435268 [PMID: 23991417]
3. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16: 658-672 [PMID: 14557292 DOI: 10.1128/CMR.16.4.658-672.2003]
4. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010; 7: 503-514 [PMID: 20664519 DOI: 10.1038/nrgastro.2010.117]
5. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, Sonnenborn U, Eckert J, Schumann RR, Wiedenmann B, Dignass AU, Sturm A. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect Immun 2006; 74: 4075-4082 [PMID: 16790781 DOI: 10.1128/IAI.01449-05]
6. Henker J, Laass MW, Blokhin BM, Maydannik VG, Bolbot YK, Elze M, Wolff C, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J 2008; 27: 494-499 [PMID: 18469732 DOI: 10.1097/INF.0b013e318169034c]
7. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003; 15: 313-315 [PMID: 12610327 DOI: 10.1097/00042737-200303000-00015]
8. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1012-1018 [PMID: 18240278 DOI: 10.1002/ibd.20377]
9. Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G, Hacker J, Dobrindt U. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol 2004; 186: 5432-5441 [PMID: 15292145 DOI: 10.1128/JB.186.16.5432-5441.2004]
10. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623 [PMID: 15479682 DOI: 10.1136/gut.2003.037747]
11. Arribas B, Rodríguez-Cabezas ME, Camuesco D, Comalada M, Bailón E, Utrilla P, Nieto A, Concha A, Zarzuelo A, Gálvez J. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharideinduced sepsis in mice. Br J Pharmacol 2009; 157: 1024-1033 [PMID: 19486007 DOI: 10.1111/j.1476-5381.2009.00270.x]
12. Maltby R, Leatham-Jensen MP, Gibson T, Cohen PS, Conway T. Nutritional basis for colonization resistance by human commensal Escherichia coli strains HS and Nissle 1917 against E. coli O157: H7 in the mouse intestine. PLoS One 2013; 8: E53957 [PMID: 23349773 DOI: 10.1371/journal.pone.0053957]
13. Reissbrodt R, Hammes WP, dal Bello F, Prager R, Fruth A, Hantke K, Rakin A, Starcic-Erjavec M, Williams PH. Inhibition of growth of Shiga toxin-producing Escherichia coli by nonpathogenic Escherichia coli. FEMS Microbiol Lett 2009; 290: 62-69 [PMID: 19016876 DOI: 10.1111/j.1574-6968.2008.01405.x]
14. Lasaro MA, Salinger N, Zhang J, Wang Y, Zhong Z, Goulian M, Zhu J. F1C fimbriae play an important role in biofilm formation and intestinal colonization by the Escherichia coli commensal strain Nissle 1917. Appl Environ Microbiol 2009; 75: 246-251 [PMID: 18997018 DOI: 10.1128/AEM.01144-08]
15. Troge A, Scheppach W, Schroeder BO, Rund SA, Heuner K, Wehkamp J, Stange EF, Oelschlaeger TA. More than a marine propeller-The flagellum of the probiotic Escherichia coli strain Nissle 1917 is the major adhesin mediating binding to human mucus. Int J Med Microbiol 2012; 302: 304-314 [PMID: 23131416 DOI: 10.1016/j.ijmm.2012.09.004]
16. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 45-56 [PMID: 12848625 DOI: 10.1046/j.1365-2036.2003.01638.x]
17. Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, Sonnenborn U, Nuding S, Bengmark S, Fellermann K, Schröder JM, Stange EF. NF-kappaB-and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: A novel effect of a probiotic bacterium. Infect Immun 2004; 72: 5750-5758 [PMID: 15385474 DOI: 10.1128/IAI.72.10.5750-5758.2004]
18. Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007; 75: 2399-2407 [PMID: 17283097 DOI: 10.1128/IAI.01563-06]
19. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007; 9: 804-816 [PMID: 17087734 DOI: 10.1111/j.1462-5822.2006.00836.x]
20. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004; 286: G613-G626 [PMID: 15010363 DOI: 10.1152/ajpgi.00341.2003]
21. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, Bleich A, Bruder D, Franzke A, Rogler G, Suerbaum S, Buer J, Gunzer F, Westendorf AM. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007; 2: E1308 [PMID: 18074031 DOI: 10.1371/journal. pone.0001308]
22. Helwig U, Lammers KM, Rizzello F, Brigidi P, Rohleder V, Caramelli E, Gionchetti P, Schrezenmeir J, Foelsch UR, Schreiber S, Campieri M. Lactobacilli, bifidobacteria and E. coli nissle induce pro-and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol 2006; 12: 5978-5986 [PMID: 17009396 DOI: 10.3748/wjg.v12.i37.5978]
23. Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazalé T, Raupach B, Eckert J, Schumann RR, Enders C, Sonnenborn U, Wiedenmann B, Dignass AU. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 2005; 73: 1452-1465 [PMID: 15731043 DOI: 10.1128/IAI.73.3.1452-1465.2005]
24. Grozdanov L, Zähringer U, Blum-Oehler G, Brade L, Henne A, Knirel YA, Schombel U, Schulze J, Sonnenborn U, Gottschalk G, Hacker J, Rietschel ET, Dobrindt U. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 2002; 184: 5912-5925 [PMID: 12374825 DOI: 10.1128/JB.184.21.5912-5925.2002]
25. Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, Göttl C, Dunger N, Grunwald N, Schölmerich J, Rath HC. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004; 11: 372-378 [PMID: 15013990 DOI: 10.1128/cdli.11.2.372-378.2004]
26. Kokesová A, Frolová L, Kverka M, Sokol D, Rossmann P, Bártová J, Tlaskalová-Hogenová H. Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia Microbiol (Praha) 2006; 51: 478-484 [PMID: 17176771 DOI: 10.1007/BF02931595]
27. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Doubleblind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858 [PMID: 9354192 DOI: 10.1046/j.1365-2036.1997.00225.x]
28. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999; 354: 635-639 [PMID: 10466665 DOI: 10.1016/S0140-6736(98)06343-0]
29. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010; 10: 13 [PMID: 20398311 DOI: 10.1186/1472-6882-10-13]
30. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: A systematic review of intervention studies in adult patients. Drugs 2012; 72: 803-823 [PMID: 22512365 DOI: 10.2165/11632710-000000000-00000]
31. Losurdo G, Iannone A, Contaldo A, Ierardi E, Di Leo A, Principi M. Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis. J Gastrointestin Liver Dis 2015; 24: 499-505 [PMID: 26697577]
32. Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial. J Crohns Colitis 2014; 8: 1498-1505 [PMID: 24972748 DOI: 10.1016/j.crohns.2014.06.001]
33. Henker J, Müller S, Laass MW, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: An open-label pilot study. Z Gastroenterol 2008; 46: 874-875 [PMID: 18810672 DOI: 10.1055/s-2008-1027463]
34. Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J. A doubleblind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012; 27: 467-474 [PMID: 22130826 DOI: 10.1007/s00384-011-1363-9]
35. Rózanska D, Regulska-Ilow B, Choroszy-Król I, Ilow R. [The role of Escherichia coli strain Nissle 1917 in the gastro-intestinal diseases]. Postepy Hig Med Dosw (Online) 2014; 68: 1251-1256 [PMID: 25380207 DOI: 10.5604/17322693.1127882]
36. Plassmann D, Schulte-Witte H. [Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): A retrospective survey]. Med Klin (Munich) 2007; 102: 888-892 [PMID: 17992479]
37. Krammer HJ, Kämper H, von Bünau R, Zieseniss E, Stange C, Schlieger F, Clever I, Schulze J. [Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): Results of a prospective study of the records of 3,807 patients]. Z Gastroenterol 2006; 44: 651-656 [PMID: 16902895 DOI: 10.1055/s-2006-926909]
38. Behnsen J, Deriu E, Sassone-Corsi M, Raffatellu M. Probiotics: Properties, examples, and specific applications. Cold Spring Harb Perspect Med 2013; 3: A010074 [PMID: 23457295 DOI: 10.1101/cshperspect.a010074]
39. Möllenbrink M, Bruckschen E. [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)]. Med Klin (Munich) 1994; 89: 587-593 [PMID: 7815986]
40. Henker J, Laass M, Blokhin BM, Bolbot YK, Maydannik VG, Elze M, Wolff C, Schulze J. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007; 166: 311-318 [PMID: 17287932 DOI: 10.1007/s00431-007-0419-x]
41. Tromm A, Niewerth U, Khoury M, Baestlein E, Wilhelms G, Schulze J, Stolte M. The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: First results of an open-label trial. Z Gastroenterol 2004; 42: 365-369 [PMID: 15136935 DOI: 10.1055/s-2004-812709]